米非司酮与黄体酮拮抗剂避免药物流产:一项范围综述。

IF 0.4 Q4 MEDICAL ETHICS
Linacre Quarterly Pub Date : 2023-11-01 Epub Date: 2023-05-29 DOI:10.1177/00243639231176592
Paul L C DeBeasi
{"title":"米非司酮与黄体酮拮抗剂避免药物流产:一项范围综述。","authors":"Paul L C DeBeasi","doi":"10.1177/00243639231176592","DOIUrl":null,"url":null,"abstract":"<p><p>The safety and efficacy of mifepristone antagonization with progesterone to avert medication abortion, also known as abortion pill rescue, is a subject of vigorous debate. Two prominent medical associations have taken positions that either entirely reject or fully support its use. This scoping review aimed to gain insight into the safety and efficacy of its use. Analysis of 16 studies showed that the continuing pregnancy rate after ingesting mifepristone alone is ≦25 percent for gestational ages ≦49 days. Analysis of four studies showed that two-thirds of the women who changed their minds and received progesterone after initiating their medication abortion with mifepristone could safely continue their pregnancies. There is no increased maternal or fetal risk from using bioidentical progesterone in early pregnancy. If a woman has already taken mifepristone for her medication abortion and then changes her mind, timely supplementation with progesterone may allow her pregnancy to continue. The conclusion that mifepristone antagonization with progesterone is a safe and effective treatment has implications for medication abortion informed consent. <b>Summary:</b> Two-thirds of the women who changed their minds and received progesterone after initiating their medication abortion with mifepristone could safely continue their pregnancies. If a woman has already taken mifepristone for her medication abortion and then changes her mind, timely supplementation with progesterone may allow her pregnancy to continue. Physicians should disclose this treatment option to their patients at the time of informed consent.</p>","PeriodicalId":44238,"journal":{"name":"Linacre Quarterly","volume":"90 4","pages":"395-407"},"PeriodicalIF":0.4000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638961/pdf/","citationCount":"0","resultStr":"{\"title\":\"Mifepristone Antagonization with Progesterone to Avert Medication Abortion: A Scoping Review.\",\"authors\":\"Paul L C DeBeasi\",\"doi\":\"10.1177/00243639231176592\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The safety and efficacy of mifepristone antagonization with progesterone to avert medication abortion, also known as abortion pill rescue, is a subject of vigorous debate. Two prominent medical associations have taken positions that either entirely reject or fully support its use. This scoping review aimed to gain insight into the safety and efficacy of its use. Analysis of 16 studies showed that the continuing pregnancy rate after ingesting mifepristone alone is ≦25 percent for gestational ages ≦49 days. Analysis of four studies showed that two-thirds of the women who changed their minds and received progesterone after initiating their medication abortion with mifepristone could safely continue their pregnancies. There is no increased maternal or fetal risk from using bioidentical progesterone in early pregnancy. If a woman has already taken mifepristone for her medication abortion and then changes her mind, timely supplementation with progesterone may allow her pregnancy to continue. The conclusion that mifepristone antagonization with progesterone is a safe and effective treatment has implications for medication abortion informed consent. <b>Summary:</b> Two-thirds of the women who changed their minds and received progesterone after initiating their medication abortion with mifepristone could safely continue their pregnancies. If a woman has already taken mifepristone for her medication abortion and then changes her mind, timely supplementation with progesterone may allow her pregnancy to continue. Physicians should disclose this treatment option to their patients at the time of informed consent.</p>\",\"PeriodicalId\":44238,\"journal\":{\"name\":\"Linacre Quarterly\",\"volume\":\"90 4\",\"pages\":\"395-407\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638961/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Linacre Quarterly\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/00243639231176592\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/5/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICAL ETHICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Linacre Quarterly","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/00243639231176592","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/5/29 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"MEDICAL ETHICS","Score":null,"Total":0}
引用次数: 0

摘要

米非司酮与黄体酮拮抗避免药物流产的安全性和有效性,也被称为流产药抢救,是一个激烈争论的主题。两个著名的医学协会采取了完全反对或完全支持使用这种药物的立场。这项范围审查旨在深入了解其使用的安全性和有效性。16项研究分析显示,孕龄≦49天,单独服用米非司酮后继续妊娠率≦25%。对四项研究的分析表明,三分之二的妇女在开始使用米非司酮进行药物流产后改变主意并接受黄体酮治疗,可以安全地继续怀孕。在妊娠早期使用生物同型黄体酮不会增加母体或胎儿的风险。如果妇女已经服用米非司酮进行药物流产,然后改变主意,及时补充黄体酮可能使她的妊娠继续。结论米非司酮与黄体酮拮抗是一种安全有效的治疗方法,对药物流产知情同意具有重要意义。总结:三分之二的妇女在开始米非司酮药物流产后改变主意并接受黄体酮治疗后可以安全地继续妊娠。如果妇女已经服用米非司酮进行药物流产,然后改变主意,及时补充黄体酮可能使她的妊娠继续。医生应在知情同意时向患者披露这种治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Mifepristone Antagonization with Progesterone to Avert Medication Abortion: A Scoping Review.

The safety and efficacy of mifepristone antagonization with progesterone to avert medication abortion, also known as abortion pill rescue, is a subject of vigorous debate. Two prominent medical associations have taken positions that either entirely reject or fully support its use. This scoping review aimed to gain insight into the safety and efficacy of its use. Analysis of 16 studies showed that the continuing pregnancy rate after ingesting mifepristone alone is ≦25 percent for gestational ages ≦49 days. Analysis of four studies showed that two-thirds of the women who changed their minds and received progesterone after initiating their medication abortion with mifepristone could safely continue their pregnancies. There is no increased maternal or fetal risk from using bioidentical progesterone in early pregnancy. If a woman has already taken mifepristone for her medication abortion and then changes her mind, timely supplementation with progesterone may allow her pregnancy to continue. The conclusion that mifepristone antagonization with progesterone is a safe and effective treatment has implications for medication abortion informed consent. Summary: Two-thirds of the women who changed their minds and received progesterone after initiating their medication abortion with mifepristone could safely continue their pregnancies. If a woman has already taken mifepristone for her medication abortion and then changes her mind, timely supplementation with progesterone may allow her pregnancy to continue. Physicians should disclose this treatment option to their patients at the time of informed consent.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Linacre Quarterly
Linacre Quarterly MEDICAL ETHICS-
CiteScore
0.80
自引率
40.00%
发文量
57
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信